(Press-News.org) EBViously, a spin-off from Helmholtz Munich (HMGU), is led by world-leading experts in Epstein-Barr virus biology, genetics, and immunity and was founded to develop a safe and highly effective preventive vaccine against a range of diseases caused by Epstein-Barr virus (EBV), including infectious mononucleosis, immune disorders, multiple sclerosis, and various cancers. The spin-off is based on a project of HMGU supported by the German Center for Infection Research (DZIF). The project leading to the spin-off was co-funded by the DZIF to enable GMP manufacturing allowing the start of clinical trials in 2024. EBViously will present its approach and technology at the World Vaccine Congress 2023 (April 4-6, 2023) in Washington, DC, USA.
The first vaccine candidate, named EBV-001, is based on non-infectious EBV-derived virus-like particles (VLPs). It is a highly immunogenic, multi-antigen vaccine that mimics the original viral pathogen and its complexity, delivering more than 50 viral antigens in their native conformation. EBViously has generated positive preclinical proof-of-concept data on the immunogenicity of the vaccine candidate. Moreover, the induction of a broad humoral and cellular immune response has already been demonstrated in animal models, reflecting the spectrum of antiviral immunity in humans.
VLPs resemble actual virus particles, but do not contain any viral genetic material. With the authentic structure of the virus, these empty shells signal an EBV infection to the immune system and elicit a highly specific immune response from both the humoral and the cellular parts of the immune system.
“Based on our very favorable preclinical proof-of-concept data regarding the immunogenicity of the vaccine, we are confident that EBV-001 can effectively prevent the development of infectious mononucleosis and the often associated chronic fatigue syndrome,” says Axel Polack, M.D., designated CEO of EBViously. “A GMP process has been established by a commercial CMO and our goal is to begin clinical trials in 2024.”
“As a primary indication, we are targeting the prevention of infectious mononucleosis, also known as kissing disease or glandular fever, and post-infectious fatigue/chronic fatigue (ME/CFS), a common, long-COVID-like protracted disease following infectious mononucleosis,” says Prof. Wolfgang Hammerschmidt, designated CSO of EBViously. “Other potential indications include the prevention of post-transplant lymphoproliferative disease (PTLD) and EBV-associated cancers. As infectious mononucleosis is a known risk factor for multiple sclerosis, there is great hope that our vaccine may also reduce the incidence of this chronic neurodegenerative autoimmune disease.”
About EBViously
EBViously specialises in novel vaccines based on next-generation virus-like particles. The Company is a spin-off from Helmholtz Munich (HMGU) and is led by a group of renowned experts in the field of Epstein-Barr virus research. EBViously has so far received €9.6 million in funding from Helmholtz Validierungs Fonds (HVF) and the German Center for Infection Research (DZIF). Additional collaboration partners are Ludwig-Maximilians-Universität München (LMU) and University Hospital rechts der Isar (TUM MRI).
About EBV
Epstein-Barr virus is one of the nine known herpesviruses and one of the most common viruses found in humans. It is estimated that approximately 90% of the world´s population is infected with EBV. Infections typically occur in early childhood and are usually asymptomatic. However, when infections occur later in life, they frequently cause infectious mononucleosis (“glandular fever”) and other serious complications. The virus is also associated with certain cancers – approximately 200,000 cancer cases worldwide, including several types of lymphoma, are attributed to EBV. In 2022, a large study documented that EBV infection is by far the most important risk factor for multiple sclerosis. A history of infectious mononucleosis further increases the risk.
END
DZIF-project-derived start-up “EBViously“ announces first details of its EBV vaccine candidate
2023-04-04
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Preventing urban flooding in the face of climate change
2023-04-04
Planners have come up with many innovative ways to prevent flooding caused by heavy downpours — from planting rain gardens to installing green roofs.
But in many cases, nothing works quite as well as a simple hole in the ground — a detention basin.
That’s the finding of an analysis by University of Cincinnati geography students in a research collaboration with the Hamilton County Conservation District.
Lead author and UC College of Arts and Sciences doctoral student Man Qi said cities are developing new ways to trap rainwater and direct it where it’s most wanted, especially during droughts. They call these low-impact development practices, which ...
Genome-wide CRISPR screens identify PARP inhibitor sensitivity and resistance in prostate cancer
2023-04-04
Prostate cancer tumors harboring BRCA1/2 mutations are exceptionally sensitive to PARP inhibitors, while genomic alterations in other DNA damage response (DDR) genes are less responsive. To identify previously unknown genes whose loss has a profound impact on PARP inhibitor response, researchers from Dana-Farber Brigham Cancer Center led a multinational effort to perform genome-wide CRISPR-Cas9 knockout screens. The study goal was to inform the use of PARP inhibitors beyond BRCA1/2-deficient tumors and support reevaluation ...
Aston University biomass expert calls for more exploration of power bioenergy with carbon capture and storage
2023-04-04
Professor Patricia Thornley welcomes latest UK energy security plans
But calls for more exploration of bioenergy with carbon capture and storage
She believes plans shouldn’t concentrate solely on energy such as wind and solar power.
A leading biomass scientist at Aston University has welcomed the government’s announcement to ensure UK energy is more secure.
However, Professor Patricia Thornley, director of Aston University’s Energy and Bioproducts Research Institute (EBRI), believes the government ...
DMI allows magnon-magnon coupling in hybrid perovskites
2023-04-04
An international group of researchers has created a mixed magnon state in an organic hybrid perovskite material by utilizing the Dzyaloshinskii–Moriya-Interaction (DMI). The resulting material has potential for processing and storing quantum computing information. The work also expands the number of potential materials that can be used to create hybrid magnonic systems.
In magnetic materials, quasi-particles called magnons direct the electron spin within the material. There are two types of magnons – optical and acoustic – which refer to the direction of their spin.
“Both optical and acoustic magnons propagate ...
New study in JNCCN identifies approach for improving end-of-life conversations for people with cancer
2023-04-04
PLYMOUTH MEETING, PA [April 4, 2023] — New research in the April 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that specially trained oncology infusion room nurses can improve advance care planning (ACP) for patients with advanced cancer. In this study, oncology nurses underwent an immersive, three-day training session on palliative care. As compared to patients who received standard care, those who participated in this targeted and specialized intervention had a ...
Those who support Black Lives Matter tend to be less hesitant about vaccines, UCLA study finds
2023-04-04
Efforts to encourage vaccination might do well to take advantage of the positive feelings and actions between different social groups, according to a study of attitudes toward vaccines among supporters of the Black Lives Matter movement.
The study by UCLA psychologists, published in the journal Social Science and Medicine, found that across all racial, ethnic and income groups, people who expressed support for the BLM movement were less hesitant about receiving COVID-19 vaccines than those who did not. The evidence suggests that altruistic feelings about interactions between ...
Women’s geographic access to fertility treatment “significantly higher” in the richest parts of Britain, analysis shows
2023-04-04
Geographic access to IVF and other fertility services is significantly higher in the richest parts of Britain, a new study shows.
Researchers have warned the current locations of clinics is likely reducing opportunities for those living in more deprived parts of the country to get fertility treatment.
Opportunities to have a baby may thus be influenced by a geographical lottery.
In 2020 nearly a fifth of local authorities did not have fertility clinics within a radius of 25km, meaning 1.6m women of reproductive ages had no assisted fertility ...
Was plate tectonics occurring when life first formed on Earth?
2023-04-04
Earth is a dynamic and constantly changing planet. From the formation of mountains and oceans to the eruption of volcanoes, the surface of our planet is in a constant state of flux. At the heart of these changes lies the powerful force of plate tectonics—the movements of Earth’s crustal plates. This fundamental process has shaped the current topography of our planet and continues to play a role in its future.
But what was plate tectonic activity like during early Earth? And was the process even occurring during the time when life is thought to have formed?
“The dynamic tectonic ...
AI tool gains doctors’ trust by giving advice like a colleague
2023-04-04
ITHACA, N.Y. – A new Cornell University-led study suggests that if artificial intelligence tools can counsel a doctor like a colleague – pointing out relevant research that supports the decision – then doctors can better weigh the merits of the recommendation.
The researchers will present the new study in April at the Association for Computing Machinery CHI Conference on Human Factors in Computing Systems.
Previously, most AI researchers have tried to help doctors evaluate suggestions from decision support tools by explaining how the underlying algorithm works, or what data was used to train the AI. But an ...
The American College of Chest Physicians warns of impact of Braidwood Management ruling
2023-04-04
The American College of Chest Physicians (CHEST) opposes the federal court’s March 30, 2023, ruling in Braidwood Management Inc. v. Becerra and applauds the Department of Justice for acting so swiftly to appeal this decision. Judge O’Connor’s remedies strip the guarantee of no-cost preventative benefits away from the 151 million people insured by the Affordable Care Act (ACA) and currently have access to care, such as smoking cessation services, guideline-indicated lung cancer screening, and tuberculosis testing.
“CHEST’s ...